Literature DB >> 10554011

Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice.

A F Carpentier1, L Chen, F Maltonti, J Y Delattre.   

Abstract

Phosphorothioate oligodeoxynucleotides with CpG motifs (CpG-ODNs) activate various immune cell subsets and induce production of numerous cytokines. To evaluate whether CpG-ODNs can induce rejection of established malignant tumor, A/J mice were challenged by the s.c. implantation of a syngenic neuroblastoma cell line (neuro2a) and subsequently injected with CpG-ODNs in the vicinity of the tumor. Daily injections of 10 microg CpG-ODNs for 15 days seemed to be the most potent regimen, leading to the eradication of 5-mm-diameter tumors in one-half of the animals and a significant tumor growth inhibition when compared with controls (88% reduction volume; P<0.001). CpG-ODN-cured animals were further protected against a new tumor challenge. The antitumoral effect of CpG-ODNs was dependent on CpG motifs, and natural killer cells seemed to play a critical role in tumor rejection. We conclude that immunostimulatory CpG-ODNs may induce the rejection of established tumors and warrant further evaluation as a potential immunotherapeutic agent.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10554011

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  41 in total

1.  Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides.

Authors:  Arthur M Krieg
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

2.  Hierarchical recognition of CpG motifs expressed by immunostimulatory oligodeoxynucleotides.

Authors:  D M Klinman; D Currie
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

3.  Immunostimulatory and anti-neoplasm effects of a novel palindrome CpG oligodeoxynucleotide in mice.

Authors:  Hai-yan Du; Li-hou Dong; Bi-jun Zhao; Jie Fu; Qing-qing Wang; Fang Chen; Lun Ou; Na Li; Xiao Sun; Zhong-ming Tang; Hai-feng Song
Journal:  Acta Pharmacol Sin       Date:  2012-06-25       Impact factor: 6.150

Review 4.  Synthetic oligonucleotides as modulators of inflammation.

Authors:  Dennis Klinman; Hidekazu Shirota; Debra Tross; Takashi Sato; Sven Klaschik
Journal:  J Leukoc Biol       Date:  2008-04-22       Impact factor: 4.962

5.  TLR9 activation coupled to IL-10 deficiency induces adverse pregnancy outcomes.

Authors:  Jessica E Thaxton; Roberto Romero; Surendra Sharma
Journal:  J Immunol       Date:  2009-06-26       Impact factor: 5.422

Review 6.  Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer.

Authors:  Kim N Chi
Journal:  World J Urol       Date:  2005-02-19       Impact factor: 4.226

7.  Polymorphisms of Toll-like receptor 9 are associated with nasopharyngeal carcinoma susceptibility.

Authors:  Qiong Dai; Xing Pu Li; Li Chai; Han An Long; Zhi Hui Yang
Journal:  Tumour Biol       Date:  2014-02-07

8.  Uptake, cellular distribution and novel cellular binding proteins of immunostimulatory CpG oligodeoxynucleotides in glioblastoma cells.

Authors:  Zhiren Zhang; Toni Weinschenk; Hermann J Schluesener
Journal:  Mol Cell Biochem       Date:  2005-04       Impact factor: 3.396

9.  Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy.

Authors:  Darya Alizadeh; Leying Zhang; Christine E Brown; Omar Farrukh; Michael C Jensen; Behnam Badie
Journal:  Clin Cancer Res       Date:  2010-06-22       Impact factor: 12.531

10.  CpG oligodeoxynucleotides inhibit tumor growth and reverse the immunosuppression caused by the therapy with 5-fluorouracil in murine hepatoma.

Authors:  Xian-Song Wang; Zhen Sheng; You-Bing Ruan; Yang Guang; Mu-Lan Yang
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.